Otonomy (NASDAQ:OTIC) Coverage Initiated at StockNews.com
Otonomy (NASDAQ:OTIC) Coverage Initiated at StockNews.com
(Get Rating)StockNews.com initiated coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report sent to investors on Saturday. The brokerage issued a hold rating on the biopharmaceutical company's stock.
證券新聞網啟動對股份的覆蓋 性 (納斯達克:奧迪 — 獲得評級) 在星期六發給投資者的研究報告中。該經紀公司對該生物製藥公司的股票發出了持有評級。
Separately, Piper Sandler cut shares of Otonomy from an overweight rating to a neutral rating and cut their price objective for the company from $3.00 to $0.50 in a report on Thursday, October 13th.
另外，派珀·桑德勒在 10 月 13 日（星期四）的一份報告中，將 Otonomy 的股票從超重評級削減為中性評級，並將公司的價格目標從 3.00 美元降至 0.50 美元。
Otonomy Price Performance
Otonomy 的價格表現
Shares of Otonomy stock opened at $0.07 on Friday. The firm has a fifty day moving average price of $0.11 and a 200 day moving average price of $0.66. Otonomy has a 1 year low of $0.06 and a 1 year high of $2.59. The stock has a market cap of $4.23 million, a PE ratio of -0.10 and a beta of 1.31.
本週五股票的開盤價為 0.07 美元。該公司的五十天移動平均價格為 0.11 美元，200 日移動平均價格為 0.66 美元。Otonomy 有 1 年的低點為 0.06 美元和 1 年的新高點為 2.59 美元。該股的市值為 423 萬美元，私募股比率為 -0.10，測試版為 1.31。
Institutional Trading of Otonomy
Otonomy 的機構交易
Otonomy Company Profile
音之美公司簡介
(Get Rating)
(取得評分)
Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.
Otonomy, Inc 是一家生物製藥公司，在美國開發神經病學治療藥物。該公司提供 OTO-313（N-甲基-D-天冬氨酸受體拮抗劑 gacyclidine）的可持續暴露配方，用於治療耳鳴的第二期臨床試驗；OTO-413（一種腦源性神經營養因子的持續暴露配方），用於修復耳蝸突觸病和聽力噪音困難的 IIA 期臨床試驗。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
- The Institutions Choose CarMax Over Carvana, Should You?
- Heatmap in Trading: How to Learn What Market Depth Hides
- Micron Technology Sees Chip Recovery by the End of 2023
- Three Healthcare Penny Stocks to Watch In The New Year
- 免費獲取有關 OTONNOMY 的研究報告
- 3 種工業股票可幫助建立您的 2023 觀察列表
- 機構選擇 CarMax 而不是卡瓦娜，你應該嗎？
- 交易中的熱圖：如何了解市場深度隱藏了什麼
- 美光技術將在 2023 年底前恢復芯片
- 三個醫療保健便士股在新的一年要關注
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Otonomy 日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收 Otonomy 和相關公司的最新新聞和分析師評級的簡要每日摘要。
